Biotest AG opens 12th plasma collection centre in Germany

EQS-News: Biotest AG / Key word(s): Miscellaneous
Biotest AG opens 12th plasma collection centre in Germany

19.04.2024 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE

Biotest AG opens 12th plasma collection centre in Germany

* 38 plasma collection centres in Europe to ensure long-term plasma supply



Dreieich, 19 April 2024: Biotest has officially opened its 12th plasma
collection centre in Germany in Wuppertal.

In future, plasma donors will be able to donate plasma five days a week,
from Monday to Friday, at the ultra-modern centre on Karlsplatz at 33
Friedrichstrasse. Friendly and dedicated staff provide an excellent service
for sustainable and paperless plasma donation. The new centre is operated by
Plasma Service Europe GmbH, a wholly owned subsidiary of Biotest AG, which
was founded more than 20 years ago to strengthen plasma donation in Germany.

'We are creating 27 new, highly skilled jobs at our centre. We are
particularly pleased that we can now also offer donors in Wuppertal the
opportunity to donate plasma close to home,' says centre manager Anja
Hirner.

'We would like to thank our dedicated team, the construction companies
involved and the architects for realising the project in these challenging
times. Of course, we also hope that many new donors will join us to ensure
the supply of life-saving medicines to patients worldwide,' emphasises
Henrik Oehme, Managing Director of Plasma Service Europe GmbH.

The Managing Directors of Plasma Service Europe GmbH, Marina Hohenböken and
Henrik Oehme, opened the new plasma donation centre together with the First
and Second Mayor of Wuppertal, Heiner Fragemann and Rainer Spiecker, the CDU
member of the Bundestag Jürgen Hardt as well as the SPD member of the state
parliament, Dilek Engin, and other representatives from politics and
business and exciting interview partners such as the Vice-Miss Germany Gina
Rühl from Wuppertal.

'Plasma donations are invaluable for the chronically ill. At present,
Germany imports plasma mainly from the USA to produce the drugs that Europe
needs. In order to become independent of imports from abroad, it is
important to raise public awareness of the importance of plasma donation and
to create incentives for potential donors. Together, we can help to secure
Europe's own supply of life-saving plasma through regular donations,' said
Jürgen Hardt, foreign policy spokesman for the CDU/CSU parliamentary group
in the German Bundestag.

In addition to the management of Plasma Service Europe GmbH, patient
representatives from dsai e.V., a patient organisation for congenital
immunodeficiencies, and Alpha 1 Deutschland e.V. will be on hand to provide
moving reports and testimonials about plasma donation. Silke Junge-Unbehauen
and Barbara Pixa, for example, are two of more than four million people
affected in Germany. Both women are dependent on plasma-derived medication
and have received a drug made from blood plasma. 'I can't thank the plasma
donors often enough. They make my life worth living,' says Silke
Junge-Unbehauen, thanking the plasma donors.

Biotest is thus continuing the planned expansion of its own donation centres
in Europe in order to contribute to more plasma donations after the Corona
pandemic showed how much Europe depend on plasma donations from outside the
EU.

The collected plasma is processed exclusively in Germany at Biotest AG in
Dreieich. Regular audits in Germany ensure that the high legal and internal
quality and safety requirements are met.

About human blood plasma

Human blood plasma is a raw material used to produce plasma derived
products, which are used to treat various illnesses of the immune system,
the blood system, as well as in emergency medicine. Biotest ranks as one of
the world's sixth largest plasma protein product manufacturing groups.
Biotest is one of the world's six largest manufacturers of plasma protein
products.

About Biotest

Biotest is a provider of biological therapeutics derived from human plasma.
With a value added chain that extends from pre-clinical and clinical
development to worldwide sales, Biotest has specialised primarily in the
areas of clinical immunology, haematology and intensive care medicine.
Biotest develops and markets immunoglobulins, coagulation factors and
albumin based on human blood plasma. These are used for diseases of the
immune and haematopoietic systems. Biotest has more than 2,400 employees
worldwide. The ordinary and preference shares of Biotest AG are listed in
the Prime Standard on the German stock exchange. Since May 2022, Biotest has
been a part of the Grifols Group, based in Barcelona, Spain
(www.grifols.com).

Biotest AG will now also be publishing official press releases via X. You
can find us at: https://twitter.com/BiotestAG

IR contact

Dr Monika Baumann (Buttkereit)

Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Dirk Neumüller

Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201

Preference shares: securities' ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart,
Tradegate

Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.


---------------------------------------------------------------------------

19.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Biotest AG
                   Landsteinerstraße 5
                   63303 Dreieich
                   Germany
   Phone:          0 61 03 - 8 01-0
   Fax:            0 61 03 - 8 01-150
   E-mail:         ir@biotest.com
   Internet:       www.biotest.de
   ISIN:           DE0005227235, DE0005227201
   WKN:            522723, 522720
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1883983

End of News EQS News Service
---------------------------------------------------------------------------

1883983 19.04.2024 CET/CEST